BioLight Life Sciences Balance Sheet Health
Financial Health criteria checks 4/6
BioLight Life Sciences has a total shareholder equity of ₪30.3M and total debt of ₪0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₪33.5M and ₪3.2M respectively.
Key information
0%
Debt to equity ratio
₪0
Debt
| Interest coverage ratio | n/a |
| Cash | ₪8.64m |
| Equity | ₪30.30m |
| Total liabilities | ₪3.15m |
| Total assets | ₪33.45m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BOLT's short term assets (₪9.1M) exceed its short term liabilities (₪2.3M).
Long Term Liabilities: BOLT's short term assets (₪9.1M) exceed its long term liabilities (₪836.0K).
Debt to Equity History and Analysis
Debt Level: BOLT is debt free.
Reducing Debt: BOLT had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BOLT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BOLT has less than a year of cash runway if free cash flow continues to grow at historical rates of 17.4% each year.